Weight loss drugs benefit from a clear, measurable endpoint and a clinical infrastructure already oriented toward chronic metabolic disease
Given its critical role in maintaining physiological homeostasis, abnormal fluctuations in HS concentrations have been linked to various pathological conditions, including diabetes [21], hypertension [22], atherosclerosis [23], and gastrointestinal diseases [24]
Resmetirom, already approved by the FDA for adults with non-cirrhotic MASH and stage F2F3 fibrosis, is ideal for lean or weight-stable patients with progressive fibrogenesis or atherogenic dyslipidemia
With offices in New York City and Princeton, NJ, Noom has been named one of Inc.'s Best Places to Work and Fortune's Best Workplaces in Technology
They are deeply personalized, medically guided journeys
Tirzepatide is a 39-amino-acid peptide with a complex structure